FALLOPIAN TUBE CANCERS
Clinical trials for FALLOPIAN TUBE CANCERS explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE CANCERS trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE CANCERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to keep ovarian cancer at bay
Disease control Recruiting nowThis study tests whether a combination of two drugs (a PARP inhibitor and an angiogenesis inhibitor) can help keep advanced ovarian, fallopian-tube, or primary peritoneal cancer from coming back after initial treatment. About 120 adults with a specific genetic feature (HRD) will …
Matched conditions: FALLOPIAN TUBE CANCERS
Phase: PHASE2, PHASE3 • Sponsor: N.N. Alexandrov National Cancer Centre • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug combo aims to shrink ovarian tumors before surgery
Disease control Recruiting nowThis study tests a new drug called TORL-1-23 given with standard chemotherapy before surgery for women with advanced ovarian cancer. About 60 participants with stage III or IV disease will receive the combination to see if it is safe and helps shrink tumors more effectively. The …
Matched conditions: FALLOPIAN TUBE CANCERS
Phase: PHASE1, PHASE2 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New drug aimed at Hard-to-Treat ovarian cancer shows promise in trial
Disease control Recruiting nowThis study tests a drug called mirvetuximab soravtansine (MIRV) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy and has high levels of a protein called FRα. The drug delivers a cancer-killing agent directly to tumor ce…
Matched conditions: FALLOPIAN TUBE CANCERS
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC